What is Tempus?
Tempus AI, Inc. operates at the intersection of machine learning, clinical data science, and advanced genomic diagnostics. The company has built one of the world's largest libraries of clinical and molecular data, which it utilizes to transform how medical practitioners approach complex conditions such as oncology, cardiology, and neuropsychiatry. By unifying disparate patient history fragments with deep molecular sequencing, the platform generates multimodal profiles that enable highly tailored, precision-based therapeutic models. This algorithmic approach allows clinicians to move beyond traditional, one-size-fits-all treatments, identifying hidden diagnostic risks and forecasting patient responses to specific chemical interventions with unprecedented accuracy.
How much funding has Tempus raised?
Tempus has raised a total of $2.1B across 12 funding rounds:
Series B
$50M
Series C
$70M
Series D
$80M
Series E
$110M
Series F
$200M
Multiple Rounds
$550M
Other Financing Round
$275M
Stock Offering
$410.7M
Debt
$300M
Series B (2017): $50M, investors not publicly disclosed
Series C (2017): $70M supported by Revolution Growth and New Enterprise Associates
Series D (2018): $80M featuring T. Rowe Price and Revolution Growth
Series E (2018): $110M backed by T. Rowe Price, Baillie Gifford, New Enterprise Associates, and Revolution Growth
Series F (2019): $200M with participation from Franklin Templeton Investments, Novo Holdings, Baillie Gifford, Revolution Growth, T. Rowe Price, and New Enterprise Associates
Series G (2020): $200M led by NEA, Baillie Gifford, Novo Holdings, Franklin Templeton, and T. Rowe Price
Other Financing Round (2020): $100M, investors not publicly disclosed
Debt (2020): $250M, investors not publicly disclosed
Other Financing Round (2022): $275M backed by Ares Capital
Stock Issuance/Offering (2024): $410.7M, investors not publicly disclosed
Debt (2025): $300M led by Ares Management Corporation
Key Investors in Tempus
T. Rowe Price
Founded in 1937, T.Rowe Price Group provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. The firm launches and manages equity and fixed income mutual funds and invests in the public equity and fixed income markets globally.
Revolution Growth
Revolution is a venture capital firm that invests in transformative technologies and iconic destinations, supporting entrepreneurs who are redefining possibilities. Their investment strategy focuses on strengthening communities through real estate and hospitality, with a significant portion of capital allocated outside of Silicon Valley.
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
What's next for Tempus?
With the successful completion of this major strategic investment, Tempus is well-positioned to accelerate its operational scale and deepen its predictive modeling capabilities. The company's focus remains on expanding its proprietary data engine to further integrate unstructured electronic health records with molecular insights. As the healthcare industry shifts toward data-driven outcomes, Tempus is expected to leverage this capital to enhance its laboratory facilities and broaden its reach across global clinical networks. The firm's ability to secure consistent financing from top-tier institutional investors suggests a long-term commitment to establishing a new standard for evidence-based, personalized medicine on a global scale.
See full Tempus company page
